Agenus plans to conduct an at-the-market offering of its common shares

Deal consists of 5 million shares to fund general corporate purposes

By Devika Patel

Knoxville, Tenn., March 2 - Agenus Inc. negotiated an at-the-market issuance sales agreement with MLV & Co. LLC on March 2, according to a prospectus supplement and 8-K filed Friday with the Securities and Exchange Commission.

The sale will consist of up to 5 million common shares.

Proceeds will be used for general corporate purposes.

Agenus is a Lexington, Mass., biotechnology company working to develop treatments for cancers and infectious diseases.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.